- Home
- GHI vs DMAC Comparison
GHI vs DMAC Comparison
Compare GHI & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHI
- DMAC
- Stock Information
- Founded
- GHI 1998
- DMAC 2000
- Country
- GHI United States
- DMAC United States
- Employees
- GHI N/A
- DMAC N/A
- Industry
- GHI Finance: Consumer Services
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- GHI Finance
- DMAC Health Care
- Exchange
- GHI Nasdaq
- DMAC Nasdaq
- Market Cap
- GHI 285.3M
- DMAC 267.7M
- IPO Year
- GHI N/A
- DMAC N/A
- Fundamental
- Price
- GHI $12.95
- DMAC $5.07
- Analyst Decision
- GHI Strong Buy
- DMAC Strong Buy
- Analyst Count
- GHI 3
- DMAC 3
- Target Price
- GHI $16.50
- DMAC $8.00
- AVG Volume (30 Days)
- GHI 49.4K
- DMAC 74.9K
- Earning Date
- GHI 05-07-2025
- DMAC 03-17-2025
- Dividend Yield
- GHI 11.32%
- DMAC N/A
- EPS Growth
- GHI N/A
- DMAC N/A
- EPS
- GHI 0.76
- DMAC N/A
- Revenue
- GHI $32,275,700.00
- DMAC N/A
- Revenue This Year
- GHI N/A
- DMAC N/A
- Revenue Next Year
- GHI N/A
- DMAC N/A
- P/E Ratio
- GHI $17.20
- DMAC N/A
- Revenue Growth
- GHI N/A
- DMAC N/A
- 52 Week Low
- GHI $10.12
- DMAC $2.14
- 52 Week High
- GHI $16.82
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- GHI 54.29
- DMAC 37.74
- Support Level
- GHI $12.85
- DMAC $5.49
- Resistance Level
- GHI $13.29
- DMAC $6.11
- Average True Range (ATR)
- GHI 0.37
- DMAC 0.34
- MACD
- GHI -0.00
- DMAC -0.09
- Stochastic Oscillator
- GHI 63.56
- DMAC 8.97
About GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.